BioChimPharm hosted a high-level delegation from the European Bank for Reconstruction and Development, led by Mr. Richard Porter, Managing Director of the Communications Department, together with representatives of EBRD Georgia.
During the visit, guests were hosted on a production tour by BioChimPharm’s General Manager, Rati Golijashvili, along with the BioChimPharm team. The delegation visited the historic phage manufacturing facility, which has been fully modernized in accordance with
European GMP (Good Manufacturing Practice) standards. The parties also discussed future opportunities and strategic plans.
“We would like once again to express our sincere gratitude to our strategic partners for their continuous support,” said Rati Golijashvili. “With a significant contribution from the EBRD, in 2022 we were able to modernize and fully re-equip BioChimPharm’s Phage Factory with high-tech infrastructure, advanced production lines, and equipment in line with European GMP standards. The project was implemented with the support of key partners, including the EBRD, the Ministry of Economy and Sustainable Development of Georgia, and the European Union, with a total investment in the project of EUR 6.5 million.”
Golijashvili also highlighted the broader strategic partnership: “Our cooperation with the EBRD extends to the fight against antimicrobial resistance (AMR), which is recognized as a major systemic risk with significant economic impact across multiple sectors worldwide. The EBRD considers AMR one of the most critical environmental and economic challenges. At BioChimPharm, we are committed to developing and manufacturing bacteriophage-based solutions as a viable alternative to antibiotics—helping reduce reliance on antibiotics and address the growing threat of antibiotic-resistant infections.”
During the visit, BioChimPharm presented the full production cycle of bacteriophages, as well as its flagship phage-based product, Phagyo.
BioChimPharm is a Georgian biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of bacteriophage-based pharmaceutical products. The company employs over 80 professionals and produces more than 10 registered products, including Phagyo—one of the most widely used phage-based solutions for respiratory infections.
BioChimPharm is the only GMP-certified pharmaceutical manufacturer in Georgia producing sterile liquid dosage forms and bacteriophage-based medicinal products, and remains the sole exporter of phage pharmaceuticals from the region to international markets.
The company expressed its optimism that cooperation with the EBRD will continue to deepen, paving the way for new joint initiatives and innovative projects in the future.
S
